[go: up one dir, main page]

TW201129359A - Pharmaceutical composition for the treatment of COPD - Google Patents

Pharmaceutical composition for the treatment of COPD

Info

Publication number
TW201129359A
TW201129359A TW099145166A TW99145166A TW201129359A TW 201129359 A TW201129359 A TW 201129359A TW 099145166 A TW099145166 A TW 099145166A TW 99145166 A TW99145166 A TW 99145166A TW 201129359 A TW201129359 A TW 201129359A
Authority
TW
Taiwan
Prior art keywords
copd
treatment
pharmaceutical composition
formoterol
glycopyrronium bromide
Prior art date
Application number
TW099145166A
Other languages
English (en)
Other versions
TWI495468B (zh
Inventor
Sauro Bonelli
Francesca Usberti
Enrico Zambelli
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42107420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201129359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of TW201129359A publication Critical patent/TW201129359A/zh
Application granted granted Critical
Publication of TWI495468B publication Critical patent/TWI495468B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/04—Methods of, or means for, filling the material into the containers or receptacles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B31/00—Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
    • B65B31/003—Adding propellants in fluid form to aerosol containers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B7/00—Closing containers or receptacles after filling
    • B65B7/16—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons
    • B65B7/28—Closing semi-rigid or rigid containers or receptacles not deformed by, or not taking-up shape of, contents, e.g. boxes or cartons by applying separate preformed closures, e.g. lids, covers
    • B65B7/2842—Securing closures on containers
    • B65B7/285—Securing closures on containers by deformation of the closure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Mechanical Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
TW099145166A 2009-12-23 2010-12-22 治療慢性阻塞性肺病（ｃｏｐｄ）之醫藥組成物 TWI495468B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09180671 2009-12-23

Publications (2)

Publication Number Publication Date
TW201129359A true TW201129359A (en) 2011-09-01
TWI495468B TWI495468B (zh) 2015-08-11

Family

ID=42107420

Family Applications (1)

Application Number Title Priority Date Filing Date
TW099145166A TWI495468B (zh) 2009-12-23 2010-12-22 治療慢性阻塞性肺病（ｃｏｐｄ）之醫藥組成物

Country Status (40)

Country Link
US (3) US20110150782A1 (zh)
EP (1) EP2515855B3 (zh)
JP (2) JP5914354B2 (zh)
KR (2) KR101757951B1 (zh)
CN (2) CN104055765B (zh)
AR (2) AR079726A1 (zh)
AU (3) AU2010334859A1 (zh)
BR (1) BR112012015337B8 (zh)
CA (1) CA2785321C (zh)
CL (1) CL2012001705A1 (zh)
CO (1) CO6541628A2 (zh)
CY (2) CY1115116T1 (zh)
DK (1) DK2515855T6 (zh)
EA (2) EA027778B1 (zh)
ES (1) ES2468840T7 (zh)
FI (2) FI2515855T6 (zh)
GE (1) GEP20156311B (zh)
HR (1) HRP20140582T4 (zh)
HU (1) HUS1800001I1 (zh)
IL (1) IL260932B (zh)
LT (1) LTC2515855I2 (zh)
LU (1) LUC00060I2 (zh)
MA (1) MA33823B1 (zh)
MX (1) MX2012006878A (zh)
MY (1) MY156949A (zh)
NL (1) NL300923I2 (zh)
NO (1) NO2018001I2 (zh)
NZ (1) NZ600790A (zh)
PE (2) PE20121396A1 (zh)
PH (1) PH12012501066A1 (zh)
PL (1) PL2515855T6 (zh)
PT (1) PT2515855E (zh)
RS (1) RS53391B2 (zh)
SG (1) SG181868A1 (zh)
SI (1) SI2515855T1 (zh)
TN (1) TN2012000269A1 (zh)
TW (1) TWI495468B (zh)
UA (1) UA113832C2 (zh)
WO (1) WO2011076843A2 (zh)
ZA (1) ZA201204615B (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2785321C (en) * 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Combination therapy for copd
MX340264B (es) * 2009-12-23 2016-07-04 Chiesi Farm Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.
ES2468835T3 (es) * 2009-12-23 2014-06-17 Chiesi Farmaceutici S.P.A. Terapia combinada para EPOC
RU2013142268A (ru) * 2011-02-17 2015-03-27 Сипла Лимитед Фармацевтическая композиция
CN103874483B (zh) 2011-10-11 2017-09-12 奇斯药制品公司 包衣了脂肪酸的β‑激动剂的晶体微粒
JP2016503390A (ja) * 2012-10-23 2016-02-04 シプラ・リミテッド 医薬組成物
PT3019153T (pt) * 2013-07-11 2018-12-04 Chiesi Farm Spa Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação
ES2666905T4 (es) * 2013-12-30 2018-06-07 Chiesi Farmaceutici S.P.A. Composición en solución para aerosol estable presurizada de una combinación de bromuro de glicopirronio y formoterol
SI3089735T1 (sl) 2013-12-30 2018-10-30 Chiesi Farmaceutici S.P.A. Sestavek stabilne aerosolne raztopine pod tlakom, ki vsebuje glikopironijev bromid in formoterol
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
GB201416909D0 (en) * 2014-09-25 2014-11-12 Prosonix Ltd Method of forming concentrated solution
WO2016170518A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
TWI731891B (zh) 2015-11-16 2021-07-01 義大利商吉斯藥品公司 含有抗膽鹼劑、皮質類固醇及β-腎上腺素之乾粉配方之製備方法
GB2545025A (en) * 2015-12-04 2017-06-07 Mexichem Fluor Sa De Cv Pharmaceutical composition
EP3436115B1 (en) 2016-03-31 2021-07-28 Chiesi Farmaceutici S.p.A. Aerosol inhalation device
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
PE20191043A1 (es) * 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
ES2877575T3 (es) 2016-09-19 2021-11-17 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende salmeterol
ES2956521T3 (es) * 2016-09-19 2023-12-22 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende bromuro de tiotropio
CN110582269B (zh) 2017-05-11 2023-02-28 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
KR20220155609A (ko) 2017-05-11 2022-11-23 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
MA52756A (fr) * 2018-06-04 2021-04-14 Lupin Inc Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
CN114502146A (zh) * 2019-12-02 2022-05-13 奇斯药制品公司 用于加压定量吸入器的不锈钢罐
US20230270754A1 (en) 2020-07-31 2023-08-31 Chemo Research, S.L. Combination therapy for inhalation administration
CA3193038A1 (en) 2020-10-09 2022-04-14 Enrico Zambelli A pharmaceutical formulation for pressurised metered dose inhaler
WO2023227782A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler
CN119255820A (zh) 2022-05-27 2025-01-03 奇斯药制品公司 用于加压定量吸入器的药物制剂
WO2023227781A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
WO1994013263A1 (en) 1992-12-09 1994-06-23 Jager Paul D Stabilized medicinal aerosol solution formulations
ATE283033T1 (de) 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
BR0015884A (pt) * 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
DE50211045D1 (de) 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
KR100947409B1 (ko) 2002-03-01 2010-03-12 키에시 파르마슈티시 엣스. 피. 에이. 포모테롤 초미세 조성물
EP1575588A1 (en) 2002-12-16 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Tiotropium containing hfc solution formulations
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
PT1713473E (pt) 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
DE602005007708D1 (de) * 2004-02-06 2008-08-07 Meda Pharma Gmbh & Co Kg Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1616567A1 (en) 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
GB0505545D0 (en) 2005-03-17 2005-04-27 Glaxo Group Ltd Inhalation devices
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
KR20080032136A (ko) 2005-08-01 2008-04-14 아스트라제네카 아베 흡입기 밸브
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
NZ568349A (en) 2005-12-21 2011-05-27 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE 4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
US8618160B2 (en) 2007-10-18 2013-12-31 Rose U Topical glycopyrrolate formulations
AU2010258751A1 (en) * 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
ES2467928T3 (es) 2009-12-23 2014-06-13 Chiesi Farmaceutici S.P.A. Formulación en aerosol para EPOC
MX340264B (es) * 2009-12-23 2016-07-04 Chiesi Farm Spa Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica.
ES2468835T3 (es) 2009-12-23 2014-06-17 Chiesi Farmaceutici S.P.A. Terapia combinada para EPOC
CA2785321C (en) * 2009-12-23 2018-08-21 Chiesi Farmaceutici S.P.A. Combination therapy for copd
PT3019153T (pt) * 2013-07-11 2018-12-04 Chiesi Farm Spa Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação
ES2666905T4 (es) * 2013-12-30 2018-06-07 Chiesi Farmaceutici S.P.A. Composición en solución para aerosol estable presurizada de una combinación de bromuro de glicopirronio y formoterol
SI3089735T1 (sl) * 2013-12-30 2018-10-30 Chiesi Farmaceutici S.P.A. Sestavek stabilne aerosolne raztopine pod tlakom, ki vsebuje glikopironijev bromid in formoterol
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
US10098837B2 (en) * 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
CL2012001705A1 (es) 2012-09-28
RS53391B (sr) 2014-10-31
AU2016234895A1 (en) 2016-10-13
JP2013515696A (ja) 2013-05-09
AU2018202998A1 (en) 2018-05-17
DK2515855T3 (da) 2014-06-30
NO2018001I1 (no) 2018-01-10
JP6283388B2 (ja) 2018-02-21
EP2515855B3 (en) 2023-05-03
AR079726A1 (es) 2012-02-15
CO6541628A2 (es) 2012-10-16
AU2016234895B2 (en) 2018-02-01
MX2012006878A (es) 2012-07-04
IL260932B (en) 2021-04-29
LTC2515855I2 (lt) 2019-05-10
KR101757951B1 (ko) 2017-07-13
LUC00060I2 (zh) 2018-03-16
US20190046433A1 (en) 2019-02-14
UA113832C2 (xx) 2017-03-27
EP2515855B1 (en) 2014-04-02
BR112012015337B8 (pt) 2021-05-25
NO2018001I2 (no) 2018-01-10
CN102665679B (zh) 2014-11-26
CN104055765A (zh) 2014-09-24
LTPA2018001I1 (lt) 2018-02-12
HK1197036A1 (zh) 2015-01-02
EA021917B1 (ru) 2015-09-30
EA201290375A1 (ru) 2013-01-30
CY2017047I2 (el) 2018-04-04
NL300923I1 (en) 2018-01-17
DK2515855T6 (da) 2023-06-06
SI2515855T1 (sl) 2014-08-29
ZA201204615B (en) 2013-09-25
JP2016145239A (ja) 2016-08-12
CA2785321A1 (en) 2011-06-30
CN102665679A (zh) 2012-09-12
EP2515855A2 (en) 2012-10-31
WO2011076843A3 (en) 2011-12-01
MY156949A (en) 2016-04-15
US11389401B2 (en) 2022-07-19
CY2017047I1 (el) 2018-04-04
US20150328144A1 (en) 2015-11-19
CN104055765B (zh) 2016-11-23
EA027778B1 (ru) 2017-08-31
BR112012015337B1 (pt) 2021-05-04
FIC20170064I1 (fi) 2017-12-29
FI2515855T6 (fi) 2023-06-02
JP5914354B2 (ja) 2016-05-11
PE20160853A1 (es) 2016-09-14
PL2515855T3 (pl) 2014-08-29
HK1174566A1 (zh) 2013-06-14
PL2515855T6 (pl) 2023-12-18
HRP20140582T1 (hr) 2014-08-01
EA201590179A1 (ru) 2015-09-30
MA33823B1 (fr) 2012-12-03
CY1115116T1 (el) 2016-12-14
SG181868A1 (en) 2012-07-30
KR20120103653A (ko) 2012-09-19
GEP20156311B (en) 2015-07-10
US20110150782A1 (en) 2011-06-23
ES2468840T7 (es) 2023-11-29
US10159645B2 (en) 2018-12-25
HUS1800001I1 (hu) 2018-02-28
AR115897A2 (es) 2021-03-10
BR112012015337A2 (pt) 2016-03-15
WO2011076843A2 (en) 2011-06-30
ES2468840T3 (es) 2014-06-17
HRP20140582T4 (hr) 2023-06-09
PT2515855E (pt) 2014-06-11
AU2010334859A1 (en) 2012-07-12
TN2012000269A1 (en) 2013-12-12
NL300923I2 (en) 2019-07-22
CA2785321C (en) 2018-08-21
TWI495468B (zh) 2015-08-11
NZ600790A (en) 2014-09-26
PE20121396A1 (es) 2012-10-24
RS53391B2 (sr) 2023-09-29
KR20170040392A (ko) 2017-04-12
PH12012501066A1 (en) 2016-03-02
LUC00060I1 (zh) 2018-01-18

Similar Documents

Publication Publication Date Title
TW201129359A (en) Pharmaceutical composition for the treatment of COPD
WO2011076841A3 (en) Combination therapy for copd
MX340924B (es) Composiciones farmaceuticas.
WO2012016845A3 (en) Pharmaceutical formulation comprising a phosphodiesterase inhibitor
GEP20166479B (en) Aerosol formulation for copd
CO2022012449A2 (es) Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada
MX2014004364A (es) Composiciones que comprenden sulfato de salbutamol.
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
WO2012040228A3 (en) Aerosol composition for administering drugs
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
CL2023000998A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
WO2010042701A3 (en) Corticosteroid compositions for use in treating diseases of the upper and lower airway passages
NZ591174A (en) Metered dose inhaler
CL2012000947A1 (es) Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.
MX2024014385A (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas
TH127043A (th) ผลิตภัณฑ์รวมสำหรับบำบัด copd
BR102012008322B8 (pt) formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa